PHIO PHARMACEUTICALS CORP. - COMMON STOCK

Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

16 May 2024 08:00:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

15 May 2024 13:00:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

09 May 2024 17:25:39 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

30 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

22 Apr 2024 13:10:09 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

16 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

11 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

National Spotlight Features Phio’s Innovative RNAi Technology Platform

03 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

02 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

21 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

13 Mar 2024 14:00:25 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

06 Mar 2024 10:30:59 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

31 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds

07 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

09 Nov 2023 16:30:20 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

09 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

03 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

12 Oct 2023 11:00:00 By Nasdaq GlobeNewswire

Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894

11 Oct 2023 07:30:19 By Nasdaq GlobeNewswire

Phio CEO to Speak at Wainwright Conference in New York in September

06 Sep 2023 07:30:00 By Nasdaq GlobeNewswire